A look at TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shareholders can tell us which group is the strongest. We can see that individual investors own the lion’s share of the company at 51%. In other words, the group will gain the most (or lose the most) from their investment in the company.
Individual investors clearly benefited the most after the company’s market cap rose $32 million last week.
In the chart below we zoom in on the different ownership groups of TC Biopharm (Holdings).
View our latest analysis for TC Biopharm (Holdings).
What does institutional ownership tell us about TC Biopharm (Holdings)?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they’re often more excited about a stock once it’s included in a major index. We would expect most companies to have some institutions on the register, especially as they grow.
Because institutions only own a small portion of TC Biopharm (Holdings), many may not have spent much time considering the stock. But it is clear that some have; and they liked it enough to shop. If business picks up from here, we could see a situation where more institutions are interested in buying. When multiple institutional investors are looking to buy stocks, we often see the stock price rising. Past sales performance (see below) may be an indication of future growth, but there are no guarantees.
Hedge funds don’t hold many shares in TC Biopharm (Holdings). Looking at our data, we can see that the largest shareholder is Scottish Enterprise with 11% of the shares outstanding. For comparison, the second-largest shareholder holds about 9.2% of the outstanding shares, followed by an 8.4% holding by the third-largest shareholder.
In examining our ownership data, we found that 18 of the top shareholders collectively own less than 50% of the share register, meaning no single person has a controlling interest.
Studying institutional ownership is a good way to gauge and filter a stock’s expected performance. The same can be done by studying analyst sentiment. We are not currently taking analyst reports on the stock so it is unlikely that there will be widespread coverage on the company.
TC Biopharm Insider Ownership (Holdings)
The definition of corporate insider can be subjective and varies by jurisdiction. Our data reflects individual insiders and captures at least board members. Management ultimately reports to the board of directors. However, it is not uncommon for managers to be board members, especially if they are founders or CEOs.
In general, I think insider ownership is a good thing. In some cases, however, it becomes more difficult for other shareholders to hold the board accountable for decisions.
It appears that insiders own a significant stake in TC Biopharm (Holdings) Plc. It has a market cap of just $320 million, and insiders have $40 million worth of shares in their own names. We’d say this shows the focus on shareholders, but it’s worth noting that the company is still quite small; Some insiders may have started the company. You can click here to see if these Insiders have bought or sold.
General Public Property
The general public – including retail investors – own 51% of TC Biopharm (Holdings). With this amount of ownership, individual investors can collectively play a role in decisions that affect shareholder returns, such as: B. Dividend Policy and Appointment of Directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability.
Private Equity Ownership
With a stake of 8.4%, private equity houses are able to help shape the corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally they have a shorter investment horizon and – as the name suggests – don’t invest much in publicly traded companies. After some time, they might try to sell capital and reallocate it elsewhere.
ownership of public companies
Public companies currently own 14% of the shares of TC Biopharm (Holdings). It’s hard to say for sure, but this suggests they may have intertwined business interests. This could be a strategic investment, so it’s worth watching for ownership changes in this area.
While it’s worth considering the different groups that own a business, there are other factors that are even more important. For example, consider the ever-present specter of investment risk. We have identified 5 warning signs at TC Biopharm (Holdings) (at least 2 that cannot be ignored) and understanding them should be part of your investment process.
Of course This might not be the best stock to buy. So check this out free free List of interesting companies.
Note: The figures in this article are calculated using data for the last twelve months, relating to the 12-month period ending on the last date of the month to which the financial statements are dated. This may not tally with the annual report figures for the full year.
Do you have any feedback about this article? Concerned about the content? Get in touch directly with us. Alternatively, send an email to the editorial team (at) simplywallst.com.
This Simply Wall St article is of a general nature. We provide comments based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended as financial advice. It is not a recommendation to buy or sell any stock and does not take into account your goals or financial situation. Our goal is to offer you long-term focused analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any of the stocks mentioned.
Join a paid user research session
You will receive one $30 Amazon Gift Card for 1 hour of your time while you help us create better investment tools for individual investors like you. Sign up here